|
9.30-10.45 |
Session 1 (*): |
Moderator: M. Ignatiadis |
|
|
· Finances and updates · Synopsis of the SAC · Strategies of the group · update on EORTC BCG 2022 and 2023 Retreats |
M. Ignatiadis (Brussels), F. van Duijnhoven (Amsterdam), M. Arnedos (Bordeaux) |
|
10.45-11.00 |
Coffee break |
|
|
11.00-13.00 |
Session 2 (*): |
|
|
|
To be completed |
|
|
13.00-14.00 |
Lunch |
|
|
14.00-16.00 |
Session 3 (*): |
Moderators: M. Ignatiadis, M.Arnedos |
|
|
DECRESCENDO (De-escalation after neoadjuvant trastuzumab, pertuzumab and taxol in HER2-pos. HR-neg. breast cancer with a pCR) |
E. Brain (St Cloud, Paris) |
|
|
NOBLE (EORTC 1984: neoadjuvant olaparib and durvalumab) |
E. Brain (St Cloud-Paris) |
|
|
APPALACHES (Palbociclib in elderly pts) |
H. Wildiers (Leuven) |
|
|
TREAT ctDNA (Elacestrant) |
M. Ignatiadis (Brussels) |
|
16.00-16.15 |
Coffee break |
|
|
16.15-18.30 |
Session 4: The future of Academic Research in Europe |
Moderators: G. Mac Grogan, (other tbc) |
|
|
Clinical research in elderly patients |
E. Brain (St Cloud-Paris) |
|
|
Machine learning-based and multiplexed resolution in early breast cancer |
T. Foukakis (Stockholm)
|
|
|
The assessment of cosmetic outcomes after reconstruction and its impact on choice (CINDERELLA) |
M.J. Cardoso (Lisboa)
|
|
|
Locoregional surgery after primary endocrine therapy |
F. van Duijnhoven (Amsterdam) |
|
|
Challenging academic research: how to improve EORTC and BIG relationship |
D. Cameron (Edinburgh) |
(*) Closed to Industry